Dyslipidemias
Conditions
Brief summary
This study is a large-scale, prospective, multi-site, and non-interventional observational study to observe the change and safety of dyslipidemia management status when administering statin+etimib complex drugs in patients with dyslipidemia.
Detailed description
All treatments, including drug administration and laboratory tests performed after administration of statin+etimib complex, are performed by the researcher's medical judgment regardless of the subject's participation in the study, and the information to be confirmed in this observational study is collected up to 24 weeks. Data collection will begin after the date of signing the research contract, and the follow-up period for each study subject is from the registration date (Visit 1) to the 24th week (Visit 3). To evaluate subjects' clinical performance in real world, we collect demographic information and medical treatment based on patient's medical records, previous dyslipidemia drug administration information, blood lipid tests and liver function tests conducted at the start date of statin+etimib compound administration and subsequent 24 weeks (± 8 weeks). In the case of safety-related information, such as abnormal cases, data shall be collected at any time during the 24-week follow-up period if there is a visit by the study subject according to daily treatment.
Interventions
DRUGStatin+Ezetimibe compound
Crezet Tablet, Litorvazet Tablet
Sponsors
Daewoong Pharmaceutical Co. LTD.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult men and women aged 19 or older as of the time of the registered visit (Visit 1) 2. Patients with dyslipidemia who are planning to administer statin+ezetimib complex or who are administering dyslipidemia complex according to the researcher's medical judgment based on the permission of statin+ezetimib complex 3. A person who can understand the information provided to him or her and voluntarily sign a written consent form
Exclusion criteria
1. Patients who overreact to the main ingredients or components of the drug in the study 2. Patients with active liver disease or patients with continuously high serum aminotransferase levels with unknown cause 3. Patients with muscle disease. 4. Pregnant women or pregnant women and nursing mothers 5. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion 6. A person who is not permitted by administration of statin+etimib complex or who falls under prohibition of administration 7. In addition to the above, a person who has determined that the researcher is not suitable for participation in this observation study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate and amount of change in LDL-C (measured LDL-C and calculated LDL-C) | 24 weeks | Rate and amount of change in LDL-C (measured LDL-C and calculated LDL-C) at 24 weeks compared to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LDL-C change rate and amount | 12 weeks | LDL-C change rate and amount at 12 weeks compared to baseline |
| Rate and amount of change in lipid variables (Non-HDL-C, HDL-C, TG, TC) | 12 weeks | Rate and amount of change in lipid variables (Non-HDL-C, HDL-C, TG, TC) at 12 weeks compared to baseline |
| Changes in ALT (Alanine Transaminase), AST (Aspartate Transaminase), and e-GFR (Estimated Glomerular Filtration Rate) | 12 weeks | Changes in ALT (Alanine Transaminase), AST (Aspartate Transaminase), and e-GFR (Estimated Glomerular Filtration Rate) at 12 weeks compared to baseline |
Countries
South Korea
Outcome results
None listed